Nateglinide

Nateglinide is a hypoglycemic agent. It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 µM. Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic beta cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine (Cay-17549). Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide (Cay-14576). Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice. It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin (STZ, Cay-13104). Formulations containing nateglinide have been used in the treatment of type 2 diabetes.Formal Name: N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine. CAS Number: 105816-04-4. Synonyms: A-4166, SDZ-DJN 608. Molecular Formula: C19H27NO3. Formula Weight: 317.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml. lambdamax: 207 nm. SMILES: CC(C)[C@@H]1CC[C@@H](C(N[C@@H](C(O)=O)CC2=CC=CC=C2)=O)CC1. InChi Code: InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1. InChi Key: OELFLUMRDSZNSF-BRWVUGGUSA-N.